Novome Biotechnologies locks in $33 mln Series A
South San Francisco-based Novome Biotechnologies Inc, a provider of living medicines for chronic diseases, has secured $33 million in Series A financing.
South San Francisco-based Novome Biotechnologies Inc, a provider of living medicines for chronic diseases, has secured $33 million in Series A financing.
Copyright PEI Media
Not for publication, email or dissemination